BIOCON Biocon Q4 FY25 results (Jan–Mar 2025) and concall
Biocon reported a robust Q4 FY25 with 15% like-for-like revenue growth, driven by strong performance across Generics, Biosimilars, and Research Services. The quarter saw key product launches and approvals, including Yesintek™ in the U.S. and Liraglutide in the U.K., alongside strategic acquisitions by Syngene. While full-year Generics EBITDA was impacted by pricing pressure and new plant costs, the company is positioned for accelerated growth with new product launches and capacity expansions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 |
| EBITDA | 685 | 752 | 1,078 |
| Net profit | 27 | 81 | 459 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
